Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Cardio-oncology is an emerging field. Most of the data available have been issued from either retrospective analysis, industry data or pharmacovigilance data. These data sources include a number of bias.
CONFUCIUS is a single tertiary centre prospective registry including all patients who have been referred for cardio-oncology assessemnt.
The objectives are to provide a comprehensive vue of cardoi-oncology, enable to detect early signals of cardiotoxicity and enhance ancillary projetcts aiming at specific populations (e.g., type of cancer) and/or drugs.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No interventions are planned | Other | Non applicable |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of cardio-toxicty | Number of patients with cardiotoxicity in a cohort of patients referred to a cardio-oncology clinic | 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Analysis of cardiotoxicity | Correlation of cardio-toxicity overall, and in predefined subgroups; statistical associatoin with outcomes. | 5 years |
| Analysis of cardioprotective strategies | Correlation between the use of cardiovascular drugs and the number of patients with cardiotoxicity. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All prosepctive patients seen in the cardio-oncology clinic. Observational data will be collected from the medical records. Outcomes measures according to scheduled follow-up visits for their cardiovascular health.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Mariana Mirabel, MD, PhD | Contact | +33156095636 | mariana.mirabel@aphp.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Paris - Centre Université de Paris | Recruiting | Paris | 75015 | France |
Not provided
| Label | URL |
|---|---|
| Hospital website | View source |
| Assistance Publique Hôpitaux de Paris' webinar | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D006331 | Heart Diseases |
| D024821 | Metabolic Syndrome |
| D001145 | Arrhythmias, Cardiac |
| ID | Term |
|---|---|
| D002318 | Cardiovascular Diseases |
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
| 5 years |
| Analysis of underlying cardiovacsular profile | Correlation between underlying cardioascular profile and the number of patients with cardiotoxicity. | 5 years |
| Analysis of arrhythmias | Correlation between incident arrhythmias and cancer drugs | 5 years |
| Precision medicine | Correlation between biomarkers with use of artificial intelligence and the number of patients with cardiotoxicity. | 5 years |
| Oncology | Adherence to oncology treatment plan as stated in the multidisciplinary team meeting in patients with cardio-oncology assessment compared to matched patients with no cardio-oncology assessment within our institution; outcomes. | 5 years |
| Cardiovascular outcomes | Assess cardiovascular outcomes (cardiovascular death, admission for heart failure, acute coronary syndrome, stroke). | 10 years |
| Any advserse event | Correlation between any adverse event, oncology treatment, and outcomes. | 5 years |
| Behaviour | Correlation of any behaviour treatment (exercice, rehabilitation, nutrition consultation) and the number of patents with cardiotoxocity. | 5 years |
| Metabolic | Correlation between oncology treatments, cardiovascular therapies, behaviour therapies and the number of patients with metabolic disorders (diabetes or dyslipidemia). | 5 years |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |